BridgeBio Pharma’s drug, Attruby, has received FDA approval for treating cardiomyopathy caused by transthyretin-mediated amyloidosis (ATTR). The drug stabilizes the abnormal protein responsible for the disease, showing significant improvement in clinical trials. Attruby is positioned to compete with Pfizer’s tafamidis, a well-established treatment for ATTR. Other companies, like Alnylam Pharmaceuticals and partners AstraZeneca and Ionis Pharmaceuticals, are also developing treatments for ATTR. Attruby’s label boasts near-complete stabilization of the protein but lacks data on all-cause mortality, a key factor in gaining market share. BridgeBio has priced Attruby slightly lower than Pfizer’s drug, with Bayer holding exclusive rights to market it in Europe.
Source link
FDA Nod for BridgeBio Brings New Competition to Blockbuster Pfizer Cardio Drug
